Patients with PWS admitted to the hospital with COVID-19 showed increased risk of in-hospital mortality, severe disease, and mechanical ventilation.

The Food and Drug Administration approved a medication this week known as VYKAT XR to treat hyperphagia — or an incessant feeling of hunger — in kids and adults with Prader-Willi syndrome. The ...

This rare disease, Prader-Willi syndrome, has been described in medical literature for nearly 70 years. But even as medical understanding of the disorder grew, efforts to develop a drug to treat i ...

on March 26 to treat hyperphagia in patients four years of age and older with Prader-Willi syndrome (PWS), is now commercially available in the U.S. Soleno has established a comprehensive support ...

Though the exact mechanism of action is unclear, it is believed that in patients with Prader-Willi syndrome, diazoxide choline reduces hyperphagia through activation of the adenosine triphosphate ...

Diazoxide choline extended-release is the first FDA-approved therapy to address hyperphagia in Prader-Willi syndrome. Soleno Therapeutics announced the medication will be available beginning in April.

54. The Food and Drug Administration on Wednesday approved the first medicine to treat people with Prader-Willi syndrome, a rare genetic disease that causes an insatiable desire to eat.

"The FDA approval of Vykat XR is an incredible achievement for the entire PWS [Prader-Willi syndrome] community. I am excited to have Vykat XR available to help treat hyperphagia, which is the ...

First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26 th, at 5:30pm ET REDWOOD CITY, Calif., ...